Anora Product of Conception ( USA Natera) at Chughtai Lab

Anora Product of Conception ( USA Natera) at Chughtai Lab

Pregnancy loss is a deeply challenging emotional and physical experience for families. Understanding the underlying cause of a miscarriage is a critical step toward healing and planning for future successful pregnancies. The Anora Product of Conception ( USA Natera) at Chughtai Lab is a premier, state-of-the-art molecular genetic test designed to identify whether a chromosomal abnormality was the cause of a miscarriage, stillbirth, or pregnancy loss. Developed by Natera, a global leader in genetic testing based in the USA, and offered in Pakistan through Chughtai Lab, this advanced diagnostic tool utilizes Single Nucleotide Polymorphism (SNP) chromosomal microarray analysis (CMA) to evaluate the fetal tissue with unparalleled precision.

Chromosomal abnormalities, such as an extra or missing chromosome, are responsible for approximately 50% to 60% of all first-trimester miscarriages. Traditional testing methods, such as karyotyping, require culturing live cells from the tissue sample. This process has a high failure rate of up to 20% to 40% because miscarriage tissue is often non-viable or contaminated with maternal cells. The Anora Product of Conception ( USA Natera) test bypasses the need for cell culture by extracting DNA directly from the tissue. This allows for a success rate of over 99%, providing grieving parents and their obstetricians with reliable, actionable answers even when the tissue sample is compromised or has been stored for an extended period.

The test evaluates all 23 pairs of chromosomes to detect aneuploidies, polyploidies (such as triploidy and tetraploidy), and submicroscopic deletions or duplications (microdeletions and microduplications). Furthermore, by analyzing a parental sample (usually a maternal blood sample or cheek swab) alongside the product of conception (POC) tissue, the Anora test can definitively rule out maternal cell contamination. This ensures that the genetic results represent the fetus rather than the mother, resolving a common limitation of older diagnostic technologies. The clinical value of this test lies in its ability to provide closure, assess the recurrence risk of future pregnancy losses, and guide future reproductive strategies, such as Preimplantation Genetic Testing (PGT) during In Vitro Fertilization (IVF).

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation and sample handling are vital to ensure the success of the Anora Product of Conception ( USA Natera) test. Patients and healthcare providers should observe the following guidelines:

• No Special Fasting: The patient does not need to fast before the tissue collection or the accompanying maternal blood draw.
• Tissue Collection Kit: Ensure that a specialized Chughtai Lab or Natera sample collection kit is obtained prior to the surgical procedure (such as a Dilation and Curettage, or D&C).
• Avoid Formalin: Miscarriage tissue must never be placed in formalin, formaldehyde, or any other chemical preservative, as these substances degrade DNA and make genetic testing impossible. The tissue must be placed in the sterile saline or transport medium provided in the kit.
• Maternal Sample Collection: A maternal blood sample (in an EDTA tube) or a maternal buccal (cheek) swab is highly recommended to be submitted alongside the tissue sample. This allows the laboratory to perform maternal cell contamination (MCC) screening, ensuring the accuracy of the fetal genetic profile.
• Paternal Sample (Optional): In some complex cases, a paternal cheek swab may also be requested to determine the parental origin of a chromosomal abnormality.

During the Procedure

The collection of the product of conception tissue typically occurs during a surgical uterine evacuation (D&C or D&E) performed by an obstetrician in a hospital setting. Alternatively, if a miscarriage occurs spontaneously at home, the patient can collect the passed tissue in a clean, sterile container containing sterile saline and deliver it immediately to Chughtai Lab. Once the sample is received at Chughtai Lab, the following clinical steps are taken:

• Sample Verification: Pathologists at Chughtai Lab inspect the specimen to identify and isolate fetal tissue (such as chorionic villi or fetal membranes) from maternal decidua to optimize the DNA yield.
• Cold Chain Logistics: The sample is carefully packaged and shipped under strict temperature-controlled conditions to Natera’s advanced molecular laboratory in the USA.
• DNA Extraction and Microarray: DNA is extracted from the fetal tissue and the maternal reference sample. The laboratory performs high-resolution SNP microarray hybridization.
• Bioinformatics Analysis: Advanced algorithms analyze millions of genetic markers to detect extra, missing, or rearranged chromosomal segments.
• Reporting: A comprehensive clinical report is generated, detailing the chromosomal status of the pregnancy loss, which is then shared with the patient and their referring physician.

When is a Anora Product of Conception ( USA Natera) Performed?

Recurrent Pregnancy Loss (RPL)

Physicians routinely recommend the Anora test for patients who have experienced two or more consecutive miscarriages. Recurrent pregnancy loss can be physically and emotionally devastating. Identifying a recurrent chromosomal issue, such as a parental translocation or recurrent aneuploidy, helps specialists determine if the losses are due to random genetic errors or an underlying genetic predisposition. This information is crucial for planning targeted medical interventions in future pregnancies.

Advanced Maternal Age

As women age, the risk of chromosomal abnormalities in oocytes increases significantly, leading to higher rates of miscarriage. For women aged 35 or older who experience a pregnancy loss, the Anora test is highly recommended. It helps determine if the miscarriage was caused by age-related aneuploidy (such as Down syndrome or Edwards syndrome). If a chromosomal error is confirmed, it provides reassurance that the loss was likely a random event, rather than a systemic maternal health issue.

Unexplained Miscarriage or Stillbirth

When a pregnancy loss occurs unexpectedly in the late first trimester, second trimester, or third trimester (stillbirth) without any apparent maternal or anatomical cause, the Anora test is performed to investigate genetic etiologies. Many structural or metabolic chromosomal anomalies do not show obvious physical signs on routine ultrasounds. The high-resolution microarray can detect submicroscopic genetic imbalances that explain the loss, providing much-needed answers to the parents.

In Vitro Fertilization (IVF) Failures

For couples undergoing assisted reproductive technology (ART) who experience a miscarriage after an embryo transfer, the Anora test is invaluable. It helps fertility specialists differentiate between a failure due to embryonic genetic abnormalities and a failure due to uterine receptivity or immunological factors. If the test reveals a chromosomal abnormality, the clinical team may recommend Preimplantation Genetic Testing for Aneuploidies (PGT-A) for subsequent IVF cycles to select genetically healthy embryos.

Family History of Genetic Abnormalities

If either partner has a family history of genetic disorders, developmental delays, or known chromosomal translocations, the Anora test is indicated following a pregnancy loss. The test can identify if the fetus inherited an unbalanced translocation, a microdeletion, or a microduplication associated with these familial traits. This allows genetic counselors to provide precise risk assessments and discuss prenatal diagnostic options for future pregnancies.

What Does a Anora Product of Conception ( USA Natera) Detect?

The Anora Product of Conception ( USA Natera) test is highly sensitive and capable of detecting a wide range of chromosomal anomalies. The clinically appropriate findings include:

• Autosomal Trisomy: The presence of an extra chromosome (e.g., Trisomy 21, Trisomy 18, Trisomy 13, Trisomy 16, or Trisomy 22), which is the most common cause of miscarriage.
• Monosomy X (Turner Syndrome): The absence of one sex chromosome in a female fetus (45,X), frequently associated with early pregnancy loss.
• Triploidy: An entire extra set of chromosomes (69 chromosomes instead of 46), usually resulting from the fertilization of an egg by two sperm.
• Tetraploidy: Four sets of chromosomes (92 chromosomes), a severe genomic duplication that leads to early embryonic demise.
• Microdeletions: Submicroscopic loss of a small segment of a chromosome (e.g., 22q11.2 deletion syndrome), which cannot be detected by standard karyotyping.
• Microduplications: Submicroscopic gain of a small chromosomal segment, which can disrupt normal fetal development.
• Maternal Cell Contamination (MCC) Exclusion: Confirms whether the analyzed DNA belongs to the fetus or is contaminated by maternal tissue, ensuring diagnostic accuracy.
• Uniparental Disomy (UPD): A condition where both chromosomes of a pair are inherited from a single parent, which can cause genetic disorders like Prader-Willi or Angelman syndromes.
• Balanced and Unbalanced Translocations: Detects structural rearrangements where segments of chromosomes are broken and rearranged.
• Mosaicism: The presence of two or more genetically distinct cell lines within the fetal tissue.
• Fetal Sex: Accurately determines the biological sex of the fetus, which can be important for identifying sex-linked genetic disorders.
• Marker Chromosomes: Identifies small, unidentified extra chromosomes that may impact development.
• Inversions: Detects segments of chromosomes that have flipped 180 degrees, which may disrupt critical genes.
• Ring Chromosomes: Formed when the ends of a chromosome are lost and the arms fuse together.
• Polyploidy: Any abnormal multiplication of the entire chromosome set.
• Absence of Heterozygosity (AOH): Identifies regions of the genome that are identical, which can indicate consanguinity or an increased risk for autosomal recessive disorders.
• Normal Male Genotype (46,XY): Confirms a genetically normal male fetus, suggesting non-genetic causes for the miscarriage.
• Normal Female Genotype (46,XX): Confirms a genetically normal female fetus, ruling out maternal cell contamination to ensure the result is fetal.

Turnaround Time and Report Access at Chughtai Lab

The Anora Product of Conception ( USA Natera) is a highly specialized molecular test that involves international logistics, DNA extraction, high-resolution microarray hybridization, and complex bioinformatics analysis. Because the sample is securely transported to Natera’s reference laboratory in the USA under strict cold chain protocols, the turnaround time is typically 3 to 4 weeks from the date of sample collection at Chughtai Lab. Once the comprehensive genetic report is finalized by Natera’s clinical geneticists, it is securely transmitted back to Chughtai Lab. Patients and their referring physicians can access the reports online through the Chughtai Lab official website portal or the Chughtai Lab mobile application. A hard copy of the report can also be collected from any main Chughtai Lab diagnostic center.

Anora Product of Conception ( USA Natera) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Chromosome Number	Euploid (46 chromosomes, 23 pairs)	Aneuploidy (Trisomy, Monosomy), Polyploidy (Triploidy, Tetraploidy)
Chromosome Structure	Intact chromosomes without structural loss or gain	Microdeletions, Microduplications, Translocations, Inversions
Maternal Cell Contamination (MCC)	Pure fetal DNA isolated and analyzed	Maternal cell contamination detected (rendering fetal results inconclusive)
Parental Origin of Anomaly	Normal biparental inheritance	Maternal or paternal origin of extra/missing chromosome identified
Uniparental Disomy (UPD)	One chromosome from each parent	Uniparental Disomy (both chromosomes inherited from one parent)
Fetal Sex Chromosomes	Normal XX (female) or XY (male)	Monosomy X (45,X), Klinefelter syndrome (47,XXY), Triplo-X (47,XXX)
Genomic Integrity (AOH)	Normal genetic diversity	Regions of homozygosity (suggesting consanguinity or risk of recessive disease)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Anora Product of Conception ( USA Natera)?

• Strategic International Partnership: Chughtai Lab partners directly with Natera USA to bring world-class genetic testing technology to patients in Pakistan.
• Advanced Cold Chain Logistics: Special transport protocols ensure that delicate tissue samples are safely delivered to the USA laboratory without degradation.
• Expert Pathologists: Highly trained pathologists at Chughtai Lab carefully examine and prepare the tissue sample to maximize fetal DNA yield.
• High Success Rate: Utilizing SNP microarray technology, the test achieves a success rate of over 99%, far exceeding traditional cell culture methods.
• Comprehensive MCC Screening: Inclusion of a maternal sample ensures that maternal DNA does not interfere with or mask the fetal genetic results.
• Convenient Report Access: Secure digital reports are accessible anytime via the Chughtai Lab mobile app and online portal.
• Nationwide Network: Convenient sample collection centers are available across all major cities in Pakistan, ensuring easy access for patients.
• Compassionate Patient Care: Chughtai Lab provides a supportive, professional, and empathetic environment for families going through pregnancy loss.